Shandong Aishi Biotechnology
Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.
Test my supplyShandong Aishi Biotechnology's purity-focus evidence is strongest for GHK-Cu and short but clean Ipamorelin, while Tirzepatide and Retatrutide have improved after earlier purity and fill misses. Tesamorelin remains the weak point, so the catalog looks dispersed rather than uniform despite very recent volume and some batch-ID gaps.
Registry records frame Shandong Aishi as a young sole-owner exporter, while TikTok presents a factory-grade production story. The report traces the ownership, claim gaps, DNS/contact stack, and unresolved penalty flags buyers cannot see from the live stats.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Shandong Aishi Biotechnology rows.
Cancel anytime
Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.
Test my supply| Date | Result | Test | Lab | Purity | Dosage | Label | COA |
|---|---|---|---|---|---|---|---|
9 Sep 2026 | Pass | GHK-Cu Shandong Aishi Biotechnology | lab name | View COA | |||
26 Aug 2026 | Pass | Tirzepatide Shandong Aishi Biotechnology | lab name | View COA | |||
26 Jun 2026 | Pass | GHK-Cu Shandong Aishi Biotechnology | lab name | View COA | |||
17 Jun 2026 | Pass | GHK-Cu Shandong Aishi Biotechnology | lab name | View COA | |||
17 Jun 2026 | Fail | Retatrutide Shandong Aishi Biotechnology | lab name | View COA | |||
17 Jun 2026 | Pass | Tesamorelin Shandong Aishi Biotechnology | lab name | View COA | |||
17 Jun 2026 | Pass | Tirzepatide Shandong Aishi Biotechnology | lab name | View COA | |||
16 Jun 2026 | Pass | GHK-Cu Shandong Aishi Biotechnology | lab name | View COA | |||
16 Jun 2026 | Pass | Tirzepatide Shandong Aishi Biotechnology | lab name | View COA | |||
5 Jun 2026 | Pass | Retatrutide Shandong Aishi Biotechnology | lab name | View COA | |||
About Shandong Aishi Biotechnology test results from Finnrick
Shandong Aishi Biotechnology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 5 peptides and 77 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Shandong Aishi Biotechnology peptides in this dataset are GHK-Cu (14 tests), Ipamorelin (4 tests) and Retatrutide (24 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 77 recent tests.
Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.
Test my supply